Market Research Logo

Global Bispecific Antibodies for Cancer Market 2019-2023

Global Bispecific Antibodies for Cancer Market 2019-2023

About this market

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period. The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets. Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years. Technavio’s analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

Market Overview

Increasing prevalence of cancer

The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.

The high cost of drug

Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.

For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


Press Release

Technavio Announces the Publication of its Research Report – Global Bispecific Antibodies for Cancer Market 2019-2023

Technavio recognizes the following companies as the key players in the global bispecific antibodies for cancer market: Amgen Inc., Astella Pharma Inc., Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd., Merus, and Regeneron Pharmaceuticals, Inc.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the emerging bispecific antibody generation platforms.”

According to the report, one of the major drivers for this market is the advantages of bispecific antibodies over monoclonal antibodies.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of BLINCYTO.

Companies Mentioned

Amgen Inc.
Astella Pharma Inc.
Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
Merus
Regeneron Pharmaceuticals, Inc.

  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global oncology therapeutics market
      • Table Segments of global oncology therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
      • Table Bispecific antibodies for cancer under development
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Customer landscape
    • Table Customer landscape
  • Market segmentation by target
    • Table Target - Market share 2018-2023 (%)
    • Comparison by target
      • Table Comparison by target
    • CD19/CD3 - Market size and forecast 2018-2023
      • Table CD19/CD3 - Market size and forecast 2018-2023 ($ millions)
      • Table CD19/CD3 - Year-over-year growth 2019-2023 (%)
    • CD30/CD16A - Market size and forecast 2018-2023
      • Table CD30/CD16A - Market size and forecast 2018-2023 ($ millions)
      • Table CD30/CD16A - Year-over-year growth 2019-2023 (%)
    • Market opportunity by target
      • Table Market opportunity by target
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Market trends
      • Table Pipeline for bispecific antibodies for cancer treatment
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Amgen Inc.
      • Table Amgen Inc. - Vendor overview
      • Table Amgen Inc. - Product segments
      • Table Amgen Inc. - Organizational developments
      • Table Amgen Inc. - Geographic focus
      • Table Amgen Inc. - Key offerings
    • Astella Pharma Inc.
      • Table Astella Pharma Inc. - Vendor overview
      • Table Astella Pharma Inc. - Business segments
      • Table Astella Pharma Inc. - Organizational developments
      • Table Astella Pharma Inc. - Key offerings
    • Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
      • Table Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Vendor overview
      • Table Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Key offerings
    • Merus
      • Table Merus - Vendor overview
      • Table Merus - Product segments
      • Table Merus - Key offerings
    • Regeneron Pharmaceuticals, Inc.
      • Table Regeneron Pharmaceuticals, Inc. - Vendor overview
      • Table Regeneron Pharmaceuticals, Inc. - Business segments
      • Table Regeneron Pharmaceuticals, Inc. - Organizational developments
      • Table Regeneron Pharmaceuticals, Inc. - Key offerings
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook